NCT05231850View on ClinicalTrials.gov

A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2027

Conditions
Colon Cancer
Interventions
DRUG

Tislelizumab

All eligible patients receive received 200 mg Tislelizumab intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER